Fatty Liver Program News Today

Madrigal Pharmaceuticals announced resmetirom is available in the US beginning on April 9, 2024, ushering in a new era of NASH management.

Better Therapeutics, Inc. , a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today announced it has submitted a request to the U.S. Food and Drug...

New analyses from the phase 3 MAESTRO-NASH support the oral daily drug's benefit for cardiovascular and hormonal outcomes over 1 year.

The international group behind the new terminology worked for 3 years to build a consensus, but convincing their peers to adopt it will require more effort.

Ozempic is a master mimicker of the hormone GLP-1, which helps the pancreas release insulin. It also acts on the brain to reduce hunger.

Ozempic is a master mimicker of the hormone GLP-1, which helps the pancreas release insulin. It also acts on the brain to reduce hunger.

Naim Alkhouri, MD, FAASLD, to Present Findings from Non-alcohol Related Fatty Liver Disease Feasibility Study Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing a

SAN FRANCISCO, June 16, 2023--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based, novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today announced the details of its poster presentation at the European Association for the Study of the Liver (EASL) Congress 2023, being held from June 21-24 in Vienna, Austria. EASL is a leading professional society and

There is some concern that the prevalence of diseases like NASH and NAFLD may increase in the coming years.

Product development should factor in the unique, complex needs of patients with NAFLD, the authors say.